Literature DB >> 23283760

Involvement of the α(1D)-adrenergic receptor in methamphetamine-induced hyperthermia and neurotoxicity in rats.

Kazue Kikuchi-Utsumi1, Mami Ishizaka, Nobuko Matsumura, Masahiko Watabe, Koji Aoyama, Nobuyuki Sasakawa, Toshio Nakaki.   

Abstract

Methamphetamine (METH) is a psychostimulant that damages nigrostriatal dopaminergic terminals, primarily by enhancing dopamine and glutamate release. α₁-adrenergic receptor (AR) subtype involved in METH-induced neurotoxicity in rats was investigated using selective α₁-AR antagonists. METH neurotoxicity was evaluated by (1) measuring body temperature; (2) determining tyrosine hydroxylase (TH) immunoreactivity levels; (3) examining levels of dopamine and its metabolites; and (4) assessing glial fibrillary acidic protein (GFAP) and microglial immunoreactivity in the striatum. METH caused a decrease in dopamine and TH levels and induced hyperthermia which is an exacerbating factor of METH neurotoxicity. Concurrently, METH increased GFAP expression and the number of activated microglia. Pretreatment with prazosin, a nonselective α₁-AR antagonist, completely abolished METH-induced decrease in both dopamine and TH and caused a partial reduction in hyperthermia. Prazosin also prevented METH-induced increase in both GFAP expression and the number of activated microglia. In vivo microdialysis analysis revealed that prazosin, however, does not alter the METH-induced dopamine release in the striatum. The neuroprotective effects of prazosin could be mimicked by a selective α(1D) antagonist, BMY 7378, but not by selective α(1A) or α(1B) antagonists. These results suggest that the α(1D)-AR is involved in METH-induced hyperthermia and neurotoxicity in rats.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23283760     DOI: 10.1007/s12640-012-9369-9

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  33 in total

1.  The role of endogenous serotonin in methamphetamine-induced neurotoxicity to dopamine nerve endings of the striatum.

Authors:  David M Thomas; Mariana Angoa Pérez; Dina M Francescutti-Verbeem; Mrudang M Shah; Donald M Kuhn
Journal:  J Neurochem       Date:  2010-09-06       Impact factor: 5.372

2.  Sympatho-adrenal involvement in methamphetamine-induced hyperthermia through skeletal muscle hypermetabolism.

Authors:  T Makisumi; K Yoshida; T Watanabe; N Tan; N Murakami; A Morimoto
Journal:  Eur J Pharmacol       Date:  1998-12-18       Impact factor: 4.432

3.  D-amphetamine fails to increase extracellular dopamine levels in mice lacking alpha 1b-adrenergic receptors: relationship between functional and nonfunctional dopamine release.

Authors:  Agnès Auclair; Susanna Cotecchia; Jacques Glowinski; Jean-Pol Tassin
Journal:  J Neurosci       Date:  2002-11-01       Impact factor: 6.167

4.  Overexpression of the alpha1B-adrenergic receptor causes apoptotic neurodegeneration: multiple system atrophy.

Authors:  M J Zuscik; S Sands; S A Ross; D J Waugh; R J Gaivin; D Morilak; D M Perez
Journal:  Nat Med       Date:  2000-12       Impact factor: 53.440

Review 5.  International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update.

Authors:  J P Hieble; D B Bylund; D E Clarke; D C Eikenburg; S Z Langer; R J Lefkowitz; K P Minneman; R R Ruffolo
Journal:  Pharmacol Rev       Date:  1995-06       Impact factor: 25.468

6.  High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity.

Authors:  Karla A Mark; Jean-Jacques Soghomonian; Bryan K Yamamoto
Journal:  J Neurosci       Date:  2004-12-15       Impact factor: 6.167

Review 7.  Current research on methamphetamine-induced neurotoxicity: animal models of monoamine disruption.

Authors:  Taizo Kita; George C Wagner; Toshikatsu Nakashima
Journal:  J Pharmacol Sci       Date:  2003-07       Impact factor: 3.337

8.  Mitochondrial complex I inhibitor rotenone-elicited dopamine redistribution from vesicles to cytosol in human dopaminergic SH-SY5Y cells.

Authors:  Masahiko Watabe; Toshio Nakaki
Journal:  J Pharmacol Exp Ther       Date:  2007-08-28       Impact factor: 4.030

9.  Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine.

Authors:  M J LaVoie; T G Hastings
Journal:  J Neurosci       Date:  1999-02-15       Impact factor: 6.167

10.  KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues.

Authors:  K Shibata; R Foglar; K Horie; K Obika; A Sakamoto; S Ogawa; G Tsujimoto
Journal:  Mol Pharmacol       Date:  1995-08       Impact factor: 4.436

View more
  2 in total

1.  Stress-induced microglial activation occurs through β-adrenergic receptor: noradrenaline as a key neurotransmitter in microglial activation.

Authors:  Shuei Sugama; Takato Takenouchi; Makoto Hashimoto; Hisayuki Ohata; Yasuhiro Takenaka; Yoshihiko Kakinuma
Journal:  J Neuroinflammation       Date:  2019-12-17       Impact factor: 8.322

Review 2.  TBHQ-Overview of Multiple Mechanisms against Oxidative Stress for Attenuating Methamphetamine-Induced Neurotoxicity.

Authors:  Yuan-Ling Zhao; Wei Zhao; Ming Liu; Lian Liu; Yun Wang
Journal:  Oxid Med Cell Longev       Date:  2020-11-27       Impact factor: 6.543

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.